Neoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC)
Conditions: Non-small Cell Lung Cancer; Hepatocellular Carcinoma Interventions: Drug: Nivolumab; Drug: BMS-813160; Drug: BMS-986253 Sponsors: Icahn School of Medicine at Mount Sinai; Bristol-Myers Squibb Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Carcinoma | Hepatocellular Carcinoma | Liver Cancer | Lung Cancer | Neoadjuvant Therapy | Non-Small Cell Lung Cancer | Research